Maintenance IVIg therapy in myasthenia gravis does not affect disease activity

Area of Science:

• Neurology
• Immunology

Background:

• Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.
• Limited data exists on the long-term efficacy of intravenous immunoglobulin (IVIg) as maintenance therapy for MG.

Purpose of the Study:

• To evaluate the effectiveness of maintenance IVIg therapy in a cohort of myasthenia gravis patients.
• To assess IVIg's role in managing disease severity and reducing other immunosuppressive treatments.

Main Methods:

• Retrospective review of 52 myasthenia gravis patients treated with IVIg from 1995-2012.
• Analysis of patients receiving maintenance IVIg for at least one year.
• Disease severity assessed using the Myasthenia Gravis Foundation of America classification.

Main Results:

• 37 out of 52 patients showed beneficial response to maintenance IVIg, averaging 5.9 years of treatment.
• Mild or moderate improvement in disease activity was observed in 23 and 14 patients, respectively; no full remission achieved.
• Beneficial response correlated with older age, bulbar presentation, seropositivity, and higher antibody titers.
• IVIg facilitated reduction in the use of pyridostigmine, prednisone, and azathioprine.

Conclusions:

• Maintenance IVIg therapy can successfully reduce myasthenia gravis symptoms and reliance on other medications.
• IVIg appears ineffective for inducing full remission or significantly altering disease activity in MG.
• IVIg should be considered a symptomatic treatment option for myasthenia gravis.